Newronika

Newronika operates at the intersection of implantable medical devices, clinical neuroscience, and digital biosignal analysis. Its core differentiation is a closed-loop deep brain stimulation approach that uses real-time neural activity, rather than relying solely on fixed stimulation settings. AlphaDBS and the related αDBS platform are designed for adaptive treatment of Parkinson’s disease, while FilterDBS supports noise-free recording of local field potentials during stimulation. WebBioBank adds a cloud-based layer for organizing neural data and supporting biomarker discovery. The company competes with established DBS providers such as Medtronic, Abbott, and Boston Scientific, which benefit from larger commercial footprints and installed clinical networks. Newronika remains much smaller, with an employee range of approximately 11–50 and a private Series B financing profile, but its specialization in adaptive stimulation and biosignal interpretation provides a focused alternative to conventional DBS platforms. Its CE-marked product and 2025 FDA IDE distinguish it from earlier-stage neurotechnology companies, although broader adoption will depend on pivotal-trial outcomes, reimbursement, physician training, and U.S. regulatory progress.

Newronika’s growth has progressed from research spin-off to regulated medical-device company over roughly 18 years. Founded in 2008 by Alberto Priori and Lorenzo Rossi, the company originated from the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. Its financing history shows staged development: a 2016 venture round of approximately $1.9 million, a $9.2 million Series A in 2019, a $2.7 million European Innovation Council grant in 2022, and a $14.2 million Series B in February 2025. The main inflection point was regulatory execution. The FDA IDE in February 2025 enabled a U.S. clinical pathway, while CE Mark approval for AlphaDBS in March 2025 supported European commercialization. In July 2026, the company announced further CE marking tied to αDBS and cloud data integration. The first ADVENT pivotal-study implant on Sep 30, 2026 marks a transition from product validation toward higher-scale clinical evidence. Leadership expansion through Keith Carlton’s September 2025 appointment and continued investment in WebBioBank suggest an emphasis on international commercialization and data-driven therapy development.